Administration of oral acyclovir suppressive therapy after neonatal herpes simplex virus disease limited to the skin, eyes and mouth: Results of a phase I/II trial

Pediatric Infectious Disease Journal

Volumn 15, Issue 3, 1996, Pages 247-254

  Kimberlin, David ^a,b   Powell, Dwight ^d   Gruber, William ^e   Diaz, Pamela ^f   Arvin, Ann ^g   Kumar, Mary ^h   Jacobs, Richard ⁱ   Van Dyke, Russell ^j   Burchett, Sandra ^k   Soong, Seng Jaw ^c   Lakeman, Alfred ^a,b   Whitley, Richard ^a,b   Laughlin, C ^l   Lakeman, A ^b   Soong, S J ^b   Kimberlin, D ^b   Stagno, S ^b   Pass, R ^b   Arvin, A ^g   Prober, C ^g   Bradley, J ^m   Spector, S ^m   Corey, L ⁿ   Demmler, G ^o   Burchett, S ^k   Adler, S ^p   Bale, J ^q   Bryson, Y ^r   Chonmaitree, T ^s   Diaz, P ^t   Gross, J ^u   Gruber, W ^v   Jacobs, R ⁱ   Keyserling, H ^w   Kinney, J ^x   Kovacs, A ^y   Kumar, M ^h   Laudert, S ^z   Leach, C ^aa   Leistikow, E ^ab   McKinney, R ^ac   Meissner, C ^ad   Modlin, J ^ae   Powell, D ^d   Rathore, M ^af   Reuman, P ^af   Robinson, J ^ag   Vaudry, W ^ag   Sander, C ^ah   Shelton, M ^ai   De Sierra, M ^aj   Stanberry, L ^ak   Starr, S ^al   Steele, R ^am   Storch, G ^an   Van Dyke, R ^ao   Weiner, L ^ap   more..

^a UAB   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c Center for Palliative Care   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^f Chicago Department of Health   (United States)

^g STANFORD UNIVERSITY   (United States)

^h CASE WESTERN RESERVE UNIVERSITY   (United States)

ⁱ UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

^j TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k BOSTON CHILDREN S HOSPITAL   (United States)

^l NATIONAL INSTITUTES OF HEALTH   (United States)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ UNIVERSITY OF WASHINGTON   (United States)

^o BAYLOR COLLEGE OF MEDICINE   (United States)

^p VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^q UNIVERSITY OF IOWA   (United States)

^r UNIVERSITY OF CALIFORNIA   (United States)

^s UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^t Chicago Department of Health   (United States)

^u MARSHFIELD CLINIC   (United States)

^v VANDERBILT UNIVERSITY   (United States)

^w EMORY UNIVERSITY   (United States)

^x UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^y UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^z WESLEY MEDICAL CENTER   (United States)

^aa UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^ab New Hanover Regional Medical Center   (United States)

^ac DUKE UNIVERSITY   (United States)

^ad TUFTS MEDICAL CENTER   (United States)

^ae DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^af UNIVERSITY OF FLORIDA   (United States)

^ag UNIVERSITY OF ALBERTA   (Canada)

^ah Baptist Memorial Center East   (United States)

^ai Children's Medical Center   (United States)

^aj HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

^ak UNIVERSITY OF CINCINNATI   (United States)

^al CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^am LOUISIANA STATE UNIVERSITY   (United States)

^an WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^ao TULANE UNIVERSITY   (United States)

^ap SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

more..

Author keywords

acyclovir; herpes simplex; Newborn; prophylaxis

Indexed keywords

ACICLOVIR;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; EYE INFECTION; FEMALE; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; INFANT; MALE; MOUTH INFECTION; NEUTROPENIA; NEWBORN INFECTION; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENCE RISK; SKIN INFECTION; TREATMENT OUTCOME; VIRUS INHIBITION;

EID: 9044244911     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199603000-00014     Document Type: Article

References (24)

1. Nahmias AJ, Keyserling HL, Kerrick GM. Herpes simplex. In: Remington JS, Klein JO, eds. Infectious diseases of the fetus and newborn infant. Philadelphia: Saunders, 1983:636-78.
2. Brown ZA, Benedetti J, Ashley R, et al. Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. N Engl J Med 1991;324:1247-52.
3. Kimberlin DW, Kimberlin DF, Andrews WW, et al. Maternal and neonatal effects of genital herpes simplex virus (HSV) shedding proximate to delivery [Abstract 1062]. Pediatr Res 1995;37:179A.
4. Whitley RJ, Arvin A, Prober C, et al. Predictors of morbidity and mortality in neonates with herpes simplex virus infections. N Engl J Med 1991;324:450-4.
5. Sarff LD, Platt LH, McCracken GH, Jr. Cerebrospinal fluid evaluation hi neonates: comparison of high-risk infants with and without meningitis. J Pediatr 1976;88:473-7.
6. American Academy of Pediatrics. Herpes simplex. In: Peter G, ed. 1994 Red Book: report of the Committee on Infectious Diseases. 23rd ed. Elk Grove Village, IL: American Academy of Pediatrics, 1994:242-52.
7. Whitley RJ, Nahmias AJ, Visitine AM, Fleming CL, Alford CA Jr., the NIAID Collaborative Antiviral Study Group. The natural history of herpes simplex virus infection of mother and newborn. Pediatrics 1980;66:489-94.
8. Whitley RJ, Yeager A, Kartus P, et al. Neonatal herpes simplex virus infection: follow-up evaluation of vidarabine therapy. Pediatrics 1983;72:778-85.
9. Whitley RJ, Alford CA Jr., Hirsch MS, et al. Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med 1986;314:144-9.
10. Quinn RP, de Miranda P, Gerald L, Good SS. A sensitive radioimmunoassay for the antiviral agent BW248U [9-(2-hydroxyethoxymethyl)guanine]. Anal Biochem 1979;98:319-28.
11. Lakeman FD, Whitley RJ, the NIAID Collaborative Antiviral Study Group. Diagnosis of herpes simplex encephalitis: application of polymerase chain reaction to cerebrospinal fluid from brain-biopsied patients and correlation with disease. J Infect Dis 1995;171:857-63.
12. Hill EL, Ellis MN, Nguyen-Dinh P. Antiviral and antiparasitic susceptibility testing. In: Balows A, ed. Manual of clinical microbiology. 5th ed. Washington, DC: American Society for Microbiology, 1991:1184-91.
13. Kimberlin DW, Spector SA, Hill EL, et al. Assays for antiviral drug resistance. Antiviral Res 1995;26:403-13.
14. Feder HM Jr., Goyal RK, Krause PJ. Acyclovir-induced neutropenia in an infant with herpes simplex encephalitis: case report. Clin Infect Dis 1995;20:1557-9.
15. Wade JC, Hintz M, McGuffin R, Springmeyer SC, Connor JD, Meyers JD. Treatment of cytomegalovirus pneumonia with high-dose acyclovir. Am J Med 1982;73(1A):249-56.
16. Wade JC, McGuffin RW, Springmeyer SC, Newton B, Singer JW, Meyers JD. Treatment of cytomegaloviral pneumonia with high-dose acyclovir and human leukocyte interferon. J Infect Dis 1983;148:557-62.
17. Bean B, Fletcher C. Neutropenia in immunocompromised patients receiving intravenous acyclovir [Abstract 786]. Presented at the 25th Interscience Conference on Antimicrobial Agents and Chemotherapy, Minneapolis, MN, September 29 to October 12, 1985.
18. McPherson ML, Plaisance KI. Neutropenia associated with oral acyclovir and multiple antibacterial agents in a patient with acquired immunodeficiency syndrome. Clin Pharm 1988;7:398-401.
19. Tuncer AM, Evis B, Kunak B, Akcayoz N, Ertem U. Erythroblastopenia and leukopenia in the patient with severe herpes zoster treated with intravenous acyclovir. Turk J Pediatr 1989;31:317-21.
20. Whitley RJ, Arvin A, Prober G, et al. A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. N Engl J Med 1991;324:444-9.
21. Whitley R, Gnann J. Acyclovir: a decade later. N Engl J Med 1992;327:782-9.
22. Hintz M, Connor JD, Spector SA, Blum MR, Keeney RE, Yeager AS. Neonatal acyelovir pharmacokinetics in patients with herpes virus infections. Am J Med 1982;73:210-14.
23. Nyquist AC, Rotbart HA, Cotton M, et al. Acyclovir-resistant neonatal herpes simplex virus infection of the larynx. J Pediatr 1994;124:967-71.
24. Kimberlin DW, Crumpacker CS, Straus SE, et al. Antiviral resistance in clinical practice. Antiviral Res 1995;26:423-38.